Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 6 of 6 for:    "PROFOUND" | France

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02987543
Recruitment Status : Active, not recruiting
First Posted : December 9, 2016
Last Update Posted : January 10, 2020
Merck Sharp & Dohme Corp.
Foundation Medicine, Inc.
Myriad Genetics, Inc.
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 4, 2019
Estimated Study Completion Date : February 5, 2021